Connect Biopharma Announces Topline Data from Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma | Connect Biopharma Holdings Ltd

Connect Biopharma Announces Topline Data from Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma

December 12, 2023 at 8:30 AM EST

Supporting Materials

Connect Biopharma Announces Topline Data from Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma 858.2 KB